TY - JOUR
T1 - Pros and cons for the development of new antiepileptic drugs
AU - Bialer, Meir
AU - Walker, Matthew C.
AU - Sander, Josemir W.
PY - 2002
Y1 - 2002
N2 - There continues to be an escalation in the number of new antiepileptic drugs, with many recently marketed drugs and many more entering clinical trials. This growth begs the question as to whether we need additional antiepileptic drugs. We consider the answer to this question from the medical perspective and also from the viewpoint of the pharmaceutical industry, health providers and from a more global, international perspective. There is undoubtedly a medical need for new antiepileptic drugs, and despite growing competition, the antiepileptic drug market remains profitable. However, in health services with limited resources, it is important that this expense is not offset by failure to research more appropriate use of existing antiepileptic drugs that may have a greater impact on healthcare. This is especially true for developing countries where resources would be much better spent on prevention and closing the treatment gap (the difference between those who can be treated and those who are treated).
AB - There continues to be an escalation in the number of new antiepileptic drugs, with many recently marketed drugs and many more entering clinical trials. This growth begs the question as to whether we need additional antiepileptic drugs. We consider the answer to this question from the medical perspective and also from the viewpoint of the pharmaceutical industry, health providers and from a more global, international perspective. There is undoubtedly a medical need for new antiepileptic drugs, and despite growing competition, the antiepileptic drug market remains profitable. However, in health services with limited resources, it is important that this expense is not offset by failure to research more appropriate use of existing antiepileptic drugs that may have a greater impact on healthcare. This is especially true for developing countries where resources would be much better spent on prevention and closing the treatment gap (the difference between those who can be treated and those who are treated).
UR - http://www.scopus.com/inward/record.url?scp=0036100537&partnerID=8YFLogxK
U2 - 10.2165/00023210-200216050-00001
DO - 10.2165/00023210-200216050-00001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 11994018
AN - SCOPUS:0036100537
SN - 1172-7047
VL - 16
SP - 285
EP - 289
JO - CNS Drugs
JF - CNS Drugs
IS - 5
ER -